Significant mitral regurgitation in patients undergoing TAVR: Mechanisms and imaging variables associated with improvement.


Journal

Echocardiography (Mount Kisco, N.Y.)
ISSN: 1540-8175
Titre abrégé: Echocardiography
Pays: United States
ID NLM: 8511187

Informations de publication

Date de publication:
04 2019
Historique:
received: 19 01 2019
accepted: 09 02 2019
pubmed: 6 3 2019
medline: 18 12 2019
entrez: 6 3 2019
Statut: ppublish

Résumé

Significant mitral regurgitation (MR) is associated with poorer outcomes in patients undergoing transcatheter aortic valve replacement (TAVR). Factors associated with MR improvement have not been studied thoroughly. Retrospective analysis of consecutive patients treated with TAVR with more than mild MR at baseline. MR evolution was assessed at 1-3 and 6-12 months after intervention. MR severity and mechanisms were assessed by echocardiography. Mitral annulus calcification (MAC) was quantified using preoperative cardiac CT. From 674 consecutive TAVR recipients, 78 with more than mild MR had a 6-12 months follow-up. Following TAVR, MR improved in 34 patients (43%), remained stable in 38 (49%) and worsened in 6 (8%). Patients with MR improvement had greater tenting area (141 ± 56 vs. 99 ± 40 mm Larger mitral valve tenting area was associated with more improvement of MR after TAVR whereas extensive MAC associated with leaflet restriction was associated with less improvement. This may help in the clinical decision-making process of TAVR candidates with concomitant MR.

Sections du résumé

BACKGROUND
Significant mitral regurgitation (MR) is associated with poorer outcomes in patients undergoing transcatheter aortic valve replacement (TAVR). Factors associated with MR improvement have not been studied thoroughly.
METHODS
Retrospective analysis of consecutive patients treated with TAVR with more than mild MR at baseline. MR evolution was assessed at 1-3 and 6-12 months after intervention. MR severity and mechanisms were assessed by echocardiography. Mitral annulus calcification (MAC) was quantified using preoperative cardiac CT.
RESULTS
From 674 consecutive TAVR recipients, 78 with more than mild MR had a 6-12 months follow-up. Following TAVR, MR improved in 34 patients (43%), remained stable in 38 (49%) and worsened in 6 (8%). Patients with MR improvement had greater tenting area (141 ± 56 vs. 99 ± 40 mm
CONCLUSION
Larger mitral valve tenting area was associated with more improvement of MR after TAVR whereas extensive MAC associated with leaflet restriction was associated with less improvement. This may help in the clinical decision-making process of TAVR candidates with concomitant MR.

Identifiants

pubmed: 30834579
doi: 10.1111/echo.14303
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

722-731

Subventions

Organisme : CIHR
ID : #FDN-143225
Pays : Canada

Informations de copyright

© 2019 Wiley Periodicals, Inc.

Auteurs

Olivier Chiche (O)

Institut Universitaire de Cardiologie et de Pneumologie de Québec - Université Laval, Québec City, Québec, Canada.
Centre Hospitalier Universitaire de Nice - Département de Cardiologie, Nice, France.

Josep Rodés-Cabau (J)

Institut Universitaire de Cardiologie et de Pneumologie de Québec - Université Laval, Québec City, Québec, Canada.

Francisco Campelo-Parada (F)

Institut Universitaire de Cardiologie et de Pneumologie de Québec - Université Laval, Québec City, Québec, Canada.

Afonso B Freitas-Ferraz (AB)

Institut Universitaire de Cardiologie et de Pneumologie de Québec - Université Laval, Québec City, Québec, Canada.

Ander Regueiro (A)

Institut Universitaire de Cardiologie et de Pneumologie de Québec - Université Laval, Québec City, Québec, Canada.

Chekrallah Chamandi (C)

Institut Universitaire de Cardiologie et de Pneumologie de Québec - Université Laval, Québec City, Québec, Canada.

Tania Rodriguez-Gabella (T)

Institut Universitaire de Cardiologie et de Pneumologie de Québec - Université Laval, Québec City, Québec, Canada.

Mélanie Côté (M)

Institut Universitaire de Cardiologie et de Pneumologie de Québec - Université Laval, Québec City, Québec, Canada.

Robert DeLarochellière (R)

Institut Universitaire de Cardiologie et de Pneumologie de Québec - Université Laval, Québec City, Québec, Canada.

Jean-Michel Paradis (JM)

Institut Universitaire de Cardiologie et de Pneumologie de Québec - Université Laval, Québec City, Québec, Canada.

Eric Dumont (E)

Institut Universitaire de Cardiologie et de Pneumologie de Québec - Université Laval, Québec City, Québec, Canada.

Daniel Doyle (D)

Institut Universitaire de Cardiologie et de Pneumologie de Québec - Université Laval, Québec City, Québec, Canada.

Siamak Mohammadi (S)

Institut Universitaire de Cardiologie et de Pneumologie de Québec - Université Laval, Québec City, Québec, Canada.

Sébastien Bergeron (S)

Institut Universitaire de Cardiologie et de Pneumologie de Québec - Université Laval, Québec City, Québec, Canada.

Philippe Pibarot (P)

Institut Universitaire de Cardiologie et de Pneumologie de Québec - Université Laval, Québec City, Québec, Canada.

Jonathan Beaudoin (J)

Institut Universitaire de Cardiologie et de Pneumologie de Québec - Université Laval, Québec City, Québec, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH